CaSm Antisense gene therapy: A novel approach for the treatment of pancreatic cancer

Anticancer Research

Volumn 23, Issue 3 A, 2003, Pages 2007-2013

  Kelley, Joseph R ^a   Fraser, Melissa M ^b   Hubbard, Josh M ^a   Watson, Dennis K ^b   Cole, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer associated Sm like oncogene; CaSm; Gene therapy; hLsm 1; Human like Sm protein; Pancreatic cancer

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CANCER ASSOCIATED SM LIKE PROTEIN; COMPLEMENTARY RNA; DNA; GEMCITABINE; GENE PRODUCT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ASSOCIATED SM LIKE ONCOGENE; CANCER CELL CULTURE; CANCER MORTALITY; CARCINOGENESIS; CELL CYCLE G1 PHASE; CONFERENCE PAPER; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SCID MOUSE; SURVIVAL TIME; UNITED STATES;

ADENOCARCINOMA; ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA, ANTISENSE; RNA-BINDING PROTEINS;

EID: 0041304769     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998 [published errata appear in CA Cancer J Clin 1998 May-Jun; 48(3):192 and 1998 Nov-Dec;48(6): 3291. CA Cancer J Clin 48: 6-29, 1998.
2. Longnecker DS and Terhune PG: What is the true rate of Kras mutation in carcinoma of the pancreas? Pancreas 17: 32-34, 1998.
3. Hruban RH, Goggins M, Parsons J and Kern SE: Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-72, 2000.
4. Goggins M, Hruban RH and Kern SE: BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156: 1767-71, 2000.
5. Wilentz RE, Chung CH, Sturm PD, Musler-A, Sohn TA, Offerhaus GJ, Yeo CJ, Hruban RH and Slebos RJ: K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82: 96-103, 1998.
6. Tsuchida T, Kijima H, Oshika Y, Tokunaga T, Abe Y, Yamazaki H, Tamaoki N, Ueyama Y, Scanlon KJ and Nakamura M: Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer: cells. Biochem Biophys Res Commun 253: 368-73, 1998.
7. Berrozpe G, Schaeffer J, Peinado MA, Real FX and Perucho M: Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58: 185-91, 1994.
8. Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H and Kuzumaki N: The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 7: 518-26, 2000.
9. Hwang RF, Gordon EM, Anderson WF and Parekh D: Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 124: 143-50; discussion 150-1, 1998.
10. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey D, Chandra J, Chada S, Fang B and Roth, JA: Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [see comments]. Ann Surg Oncol 5: 681-8, 1998.
11. Schweinfest CW, Graber MW, Chapman JM, Papas TS, Baron PL and Watson DK: CaSm: an Sm-like protein that contributes to the transformed state in cancer cells. Cancer Res 57: 2961-5, 1997.
12. Hermann H, Brahms H and Luhrmann R: snRNP Sm proteins share two evolutionarily conserved sequence motifs which are involved in Sm protein-protein interactions. Embo J 14: 207-688, 1995.
13. Kambach C, Walke S, Young R, Avis JM, de la Fortelle E, Raker VA, Luhrmann R, Li J and Nagai K: Crystal structures of two Sm protein complexes and their implications for the assembly of the spliceosomal snRNPs. Cell 96: 375-87, 1999.
14. Kambach C, Walke S and Nagai K: Structure and assembly of the spliceosomal small nuclear ribonucleoprotein particles. Curr Opin Struct Biol 9: 222-30, 1999.
15. He W and Parker R: Functions of Lsm proteins in mRNA degradation and splicing. Curr Opin Cell Biol 12: 346-50, 2000.
16. Salgado-Garrido J, Bragado-Nilsson E, Kandels-Lewis S and Seraphin B: Sm and Sm-like proteins assemble in two related complexes of deep evolutionary origin. Embo J 18: 3451-62, 1999.
17. Achsel T, Brahms H, Kastner B, Bachi A, Wilm M and Luhrmann R: A doughnut-shaped heteromer of human Sm-like proteins binds to the 3'-end of U6 snRNA, thereby facilitating U4/U6 duplex formation in vitro. Embo J 18: 5789-802, 1999.
18. Bouveret E, Rigaut G, Shevchenko A, Wilm M and Seraphin B: A Sm-like protein complex that participates in mRNA degradation. Embo J 19: 1661-71, 2000.
19. Dunckley T and Parker R: The DCP2 protein is required for mRNA decapping in Saccharomyces cerevisiae and contains a functional MutT motif. Embo J 18: 5411-22, 1999.
20. Zhao J, Kessler M, Helmling S, O'Connor JP and Moore C: Ptal, a component of yeast CF II, is required for both cleavage and poly(A) addition of mRNA precursor. Mol Cell Biol 19: 7733-40, 1999.
21. Mitchell P and Tollervey D: mRNA stability in eukaryotes. Curr Opin Genet Dev 10: 193-8, 2000.
22. Boeck R, Lapeyre B, Brown CE and Sachs AB: Capped mRNA degradation intermediates accumulate in the yeast spbS-2 mutant. Mol Cell Biol 18: 5062-72, 1998.
23. Kelley JR, Brown JM, Frasier MM, Baron PL, Schweinfest CW, Vournakis JN, Watson DK and Cole DJ: The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery 128: 353-60, 2000.
24. Kelley JR, Fraser MM, Schweinfest CW, Vournakis JN, Watson DK and Cole DJ: CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer. Surgery 130: 280-8, 2001.